Compare IMNM & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | VCEL |
|---|---|---|
| Founded | 2006 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2020 | 1996 |
| Metric | IMNM | VCEL |
|---|---|---|
| Price | $22.12 | $46.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $32.80 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 1.7M | 704.3K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.40 | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | $6,941,000.00 | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | $1,127.34 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $8.67 | $28.95 |
| 52 Week High | $27.65 | $48.75 |
| Indicator | IMNM | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 62.32 |
| Support Level | $19.28 | $32.47 |
| Resistance Level | $23.25 | N/A |
| Average True Range (ATR) | 1.36 | 1.77 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 45.98 | 60.54 |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.